#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Padeliporfin Imiquimod Clavulanic Acid Damoctocog Alfa Pegol Methylprednisolone Florbetapir (18F) Human Albumin Solution Satralizumab 64CU-PSMA I&T Anidulafungin Sym024 Doxycycline Hyclate Alks 2680 TUVATEXIB Clomifene Citrate Verapamil Hydrochloride Oregovomab Hydroxocobalamin Pelareorep Sodium Nitroprusside Dihydrate More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated drugs:
    • Infliximab
    • Carboplatin
    • Mycophenolate Mofetil
    Austria Belgium France Germany Hungary Italy +3

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Mk-1084
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Greece Hungary +5

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer metastatic
    Investigated drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    • GSK5764227
    • Topotecan
    Bulgaria Finland France Germany Greece Hungary +7

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IV
    Investigated drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    • Docetaxel
    Hungary Poland Portugal Romania Spain

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    Investigated drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Hydroxocobalamin
    • Sotorasib
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Patritumab Deruxtecan
    • Mk-1084
    • Cetuximab
    Germany Greece Hungary Italy Poland Spain

  • A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    Investigated drugs:
    • Datopotamab Deruxtecan
    • Docetaxel
    Austria Belgium France Germany Hungary Italy +2
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!